Logo
I

ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company

380 employees

ImClone Systems is a fully integrated global biopharmaceutical company committed to advancing oncology care by developing and commercializing a portfolio of targeted biologic treatments designed to address the medical needs of patients with a variety of cancers. On November 24, 2008, ImClone Systems became a wholly-owned subsidiary of Eli Lilly and Company (NYSE: LLY).

Basic info

Industry

Biotechnology Research

Sectors

Biotechnology Research

FAQ